In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SymBio Pharmaceuticals Ltd.

www.symbiopharma.com

Latest From SymBio Pharmaceuticals Ltd.

Japan Approvals Include World-First For Skyrizi, Kymriah As Asia's First CAR-T

Japan approves a large batch of new products including significant first nods globally for AbbVie's antibody for psoriasis and Japan's first gene-based therapy, as well as a pioneering first approval in Asia for a CAR-T drug.

Japan Approvals

Whiz Looks To Axcelead To Help Build Lagging Japan Venture Ecosystem

Japan was never known for its healthcare-focused venture capital funds, but Whiz Partners, Inc. is looking to fill what it sees as a void, helped by some heavy corporate hitters, and a major new collaboration with Takeda's spun out preclinical development operations in Japan.

Japan Commercial

What A Whiz! Takeda Spins Off Discovery Op Axcelead Into New Fund

Takeda has spun off into a new joint investment fund selected drug discovery operations in Japan that had been shifted to the new Axcelead business last year, further honing its focus ahead of the Shire acquisition and in a move to foster a more effective early-stage ecosystem in the country.

Japan Research and Development Strategies

Pipeline Watch: Phase III Progress With Tecentriq, Rolontis And ADV7103

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Transdermal
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • SymBio Pharmaceuticals Ltd.
  • Senior Management
  • Fuminori Yoshida, Pres. & CEO
    Kazuo Asakawa, EVP, COO
  • Contact Info
  • SymBio Pharmaceuticals Ltd.
    Phone: (81) 3 5472 1125
    Toranomon 30 Mori Bldg.
    3-2-2 Toranomon
    Minato-ku, 105-0001
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register